Secondary analysis of the CAMERA2 trial (150 combination-therapy patients with MRSA bacteraemia): in vitro synergy or additivity with a β-lactam did not change the primary 90-day mortality composite (32% vs 34%), though 14-day mortality was lower (2.9% vs 12.8%).
Secondary analysisn = 150
Soo et al. Effect of in vitro synergy and additivity of vancomycin or daptomycin plus an antistaphylococcal β-lactam for methicillin-resistant Staphylococcus aureus bacteraemia on mortality: preplanned analysis from CAMERA2